An antimetastatic study of Arg-Asp (RD) on salivary adenoid cystic carcinoma in vivo.
- Author:
Fenghe LI
1
;
Guangyan YU
;
Shenglin LI
;
Shiqi PENG
;
Jia FU
;
Dengcheng WU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antineoplastic Agents; therapeutic use; Arginine; therapeutic use; Aspartic Acid; therapeutic use; Carcinoma, Adenoid Cystic; drug therapy; prevention & control; secondary; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; prevention & control; secondary; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; prevention & control; Salivary Gland Neoplasms; drug therapy; pathology
- From: Chinese Journal of Stomatology 2002;37(2):87-89
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo test the antimetastatic effects of Arg-Asp (RD) on salivary adenoid cystic carcinoma (SACC-LM) in vivo.
METHODSRD was administered orally to experimental metastasized nude mice. The pulmonary metastatic foci number and survival were determined to assay the antimetastatic effects of RD.
RESULTS30 mg/kg, 120 mg/kg of RD demonstrated an inhibitory effect on the pulmonary metastatic foci formation. All of the tested dosages (7.5 mg/kg, 30 mg/kg, 120 mg/kg) of RD prolonged the survival.
CONCLUSIONSOral administration of RD has a antimetastatic effect on SACC-LM. RD is low toxicity.
